ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Breast Cancer

Breast Cancer

The KEYNOTE-012 trial shows that pembrolizumab has activity and acceptable toxicity as single-agent therapy in advanced triple-negative breast cancer.

Cognitive behavioral therapy may reduce long-term memory-related issues linked to chemotherapy treatment in cancer survivors.

In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.

Results of the I-SPY 2 TRIAL found that the neoadjuvant combination of T-DM1 plus pertuzumab resulted in a greater benefit to HER2-positive breast cancer patients compared with paclitaxel plus trastuzumab.

A new study found that half of women age 40 to 44 evaluated at an academic practice qualified for annual mammography screening for breast cancer.

More than half of women undertreated for their ductal carcinoma in situ may develop a recurrence of the disease or invasive breast cancer within 10 years, according to a study presented at the 2016 American Society of Breast Surgeons Annual Meeting.

Combining trastuzumab emtansine with docetaxel both with and without pertuzumab yielded promising efficacy in a phase Ib/IIa study of patients with HER2-positive locally advanced or metastatic breast cancer.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.